Skip to content

Addiction research published in 2026

Page 6 of 8: studies 101 to 120 of 149, newest first. Back to the addiction overview

Studies

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC

Research Square March 31, 2026 Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al. preprint

Abstract Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experiences, but progress has been limited by a lack of experimental models that capture these context-dependent...

“I can objectively view my trauma without feeling like I'm there”: Reddit discussions on self-reported use of psychedelics to address co-occurring substance use and mental health needs

Journal of Psychedelic Studies March 30, 2026 Emma Yuanqi Gu, Natalia M. Irvine, Megan Miller et al.

Abstract Introduction While the relationship between substance use disorders (SUD) and mental health conditions is well established, treatment for these co-occurring conditions is difficult to manage. Research on the potential for psychedelic treatments to address SUD and mental health conditions has recently seen a resurgence. This study aimed to explore narratives on the influence of...

DOI: 10.1556/2054.2026.00487 (opens in new tab) Addiction Mental health Context archaeology Exploratory research +8

Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders

Psychiatry and Clinical Psychopharmacology March 30, 2026 Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin

Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial

PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint

Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods: Adults with AUD (N = 59) received a...

Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts

Behavioral Sciences March 24, 2026 J. Richard Kendrick, Ghonwa Ahmad, Audrey Wood et al.

The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders...

DOI: 10.3390/bs16040480 (opens in new tab) Ketamine Addiction Thematic analysis Adverse effect +4

Mindfulness, Metacognition and Neuropsychological Functioning in Indian Men with Opioid Dependence: Implications for Addiction Recovery and Rehabilitation.

Annals of Neurosciences March 23, 2026 Hemant Kashyap, Lalhmingmawii Khiangte, Nandan Kumar Thakur et al.

Background: Neuropsychological functioning, metacognitive awareness and mindfulness are central to self-regulatory processes operating across cognitive and affective domains. Although global research on these constructs has increased, integrated evidence from non-Western contexts, particularly India, remains limited. Purpose: The purpose of this study was to assess and compare...

DOI: 10.1177/09727531261424995 (opens in new tab) Full text (opens in new tab) Mindfulness Metacognition Opioid dependence Neuropsychological functioning

New psychoactive substances (designer drugs): an approach to classification

Neurology Bulletin March 23, 2026 Azat R. Asadullin, Elvina A. Akhmetova, Ilia S. Efremov et al.

BACKGROUND: Substance use disorders remain a global public health problem. In recent decades, the drug market has undergone substantial changes, with traditional drugs increasingly replaced by new psychoactive substances characterized by high toxicity and strong addictive potential. Their distribution via the Internet and social media impedes control and increases risks to public health. AIM:...

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility

Frontiers in Neuroscience March 23, 2026 Malkanthi Evans, Andrew Charrette

While the limitations of existing treatment options have spurred investigations into the applicability of psychedelic therapies for chronic and treatment-resistant psychological disorders, there remain significant unresolved issues pertaining to how these treatments should be regulated and the implementation of an ethical framework for their widespread delivery in practice. Research...

Music and Psychoactive Substances: Cultural Practices, Adolescent Development and Music Therapy in Addiction Treatment

IntechOpen eBooks March 18, 2026 Jörg Fachner, Filippo Pasqualitto, Clemens Maidhof

Music and psychoactive substances play a key role in forming identity during adolescence. Grasping the historical, neurobiological, and clinical aspects of this relationship is crucial for exploring how music therapy (MT) can support recovery from substance use disorder (SUD). In this chapter, the discussion begins by framing adolescent risk-taking, including substance experimentation, as a way...

Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.

Alcohol and Alcoholism March 17, 2026 Ieva Poceviciute, Martynas Arbaciauskas, Rokas Buisas et al.

Previous studies have demonstrated that the endocannabinoid system plays a significant role in the development of alcohol use disorder (AUD), and CB1 receptor antagonists/inverse agonists show promise as a novel AUD pharmacotherapy. However, these compounds failed in clinical trials due to the severe psychiatric side effects. Non-psychoactive phytocannabinoids may have a better safety profile...

The Neuropeptidergic Modulation of Phenomenological Depth: A Review of Oxytocin’s Role in Facilitating States of Pure Consciousness

Preprints.org March 17, 2026 Yuki Ueda preprint

The nature of consciousness, specifically the state of "pure consciousness"—often characterized in contemplative traditions as a state of awareness devoid of intentional content—has transitioned from a topic of purely philosophical inquiry to a rigorous subject of neuroscientific study. This review synthesizes current clinical and neurobiological research to propose that oxytocin (OT), a...

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application

Frontiers in Pharmacology March 16, 2026 Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino

psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...

DOI: 10.3389/fphar.2026.1816812 (opens in new tab) Addiction Neurotoxicity Mechanism biology Recreational use +7

Measuring the psychoactive effects of ketamine in alcohol use disorder: When assessment shapes experience

Addiction March 11, 2026 Christina Mcanulty, Nicolas Garel

Bloy et al. [1] provide an important and methodologically rigorous secondary analysis of the Ketamine for the reduction of Alcoholic Relapse (KARE) trial, examining whether acute psychoactive effects mediate the therapeutic impact of ketamine in alcohol use disorder (AUD). Their finding that dissociative and perceptual effects did not mediate abstinence outcomes is clinically relevant, and...

DOI: 10.1111/add.70396 (opens in new tab) Ketamine Alcohol Psychoactive drug Medline +1

Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities

Pharmacological Reports March 11, 2026 Benjamin D. Brody, Dora Kanellopoulos 1 citation

Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and...

Do Mindful Partners Make a Difference? A Meta-Analytic Test of the Actor-Partner Interdependence Model in Romantic Couples

PsyArXiv Preprints March 9, 2026 preprint

Objectives: Mindfulness is consistently linked with individual well-being and relationship functioning, yet it remains unclear systemically whether mindfulness reliably “crosses over” within romantic couples — such that one partner’s mindfulness is associated with other partner’s outcomes after accounting for dyadic interdependence. We conducted a model-testing meta-analysis (MTMA) based on the...

DOI: 10.1037/cps0000382 (opens in new tab) Full text (opens in new tab) Mindfulness Actor-partner interdependence model Model-testing meta-analysis Partner effects +4

Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings

Healthcare March 3, 2026 Paul Lie, Titus Lie, Madeleine Nguyen et al. 1 citation

This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for acute suicidality. Long-term suicide rates continue to increase in the United States and in many other countries, creating a pressing public health challenge with a variety of treatment considerations. Existing standard-of-care SSRI therapeutics have...

Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy

SVOA Medical Research March 2, 2026 Olumuyiwa A. Bamgbade, Olumide O. Asaolu, Daniel O. Bamgbade et al.

Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impaired driving, and avoidable emergency care. Methods: This is an observational study of a convenience sample of twenty adult chronic pain patients who underwent regular monthly intramuscular ketamine for multimodal pain therapy. Ketamine was...

Sex and individual differences in ketamine's effects on alcohol drinking in rats.

Alcohol Clin Exp Res March 1, 2026 Sarah D Jennings, Ian Yates, Samantha K Saland et al.

Background: Effective pharmacotherapies for Alcohol Use Disorder (AUD) are lacking, and factors such as sex, drinking patterns, and timing of treatment during the addiction cycle may influence treatment efficacy. Clinical studies suggest that ketamine may be effective in AUD; however, preclinical findings have been inconclusive, likely due to varying rodent strains, intake protocols, and...

Views on Psychedelic-Assisted Therapy for Substance Use Disorders from Individuals with Opioid Use Disorder and a History of Injection-Related Infections: A Qualitative Study.

Psychedelic Medicine March 1, 2026 Veronica Szpak, Samuel Maddams, Amanda Kim et al.

New treatment options are needed to improve outcomes for patients with both opioid use disorder (OUD) and injection-related infections. Psychedelic-assisted therapy (PAT) has been suggested as a potential treatment for substance use disorders (SUD). To address this need, a qualitative study was conducted to understand the attitudes toward PAT from individuals with OUD who have survived...

The Montreal model of ketamine-therapy for alcohol use disorder and comorbid treatment-resistant depression: protocol for a feasibility trial

BMJ Open March 1, 2026 Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.

BACKGROUND: Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid antidepressant effects and has shown promise in reducing alcohol use, and acceptance and commitment therapy (ACT) can be effective for both substance use and mood disorders. This study explores the...